New approach using multiple microRNA ‘hitchhikers’ to weaken cancer cells in advance of standard therapy shows promise in preclinical models
In cancer therapeutics research, microRNAs–tiny strings of nucleotides that get churned out inside cells–have been a source of both excitement and disappointment. While preclinical studies have found that microRNAs play an important role in cancer and other diseases, two cancer clinical trials to date using microRNAs showed little response and significant toxicity. A team of investigators at Brigham and Women’s Hospital and Harvard Medical School has begun looking at these molecules in an entirely new way. Rather than modulating just one, they grouped together multiple microRNAs that naturally occur in the brain by encoding them in a small, artificial gene, and co-opted cancer cells’ molecular machinery to overproduce these groups of molecules to weaken the cells. Their approach has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The team’s results are published in Nature Communications.
“I like to think of it as hitchhiking. Cancer cells have a built-in system to produce and recognize microRNAs and we’re getting them to ‘pick up’ our sequence–which encodes multiple microRNAs–and start making more copies of them. The cellular machinery is running, and our sequence is along for the ride,” said corresponding author Pierpaolo Peruzzi, MD, PhD, an attending clinical neurosurgeon in the Department of Neurosurgery, as well as a principal investigator in the Harvey Cushing Neuro-Oncology Laboratories at the Brigham.
Peruzzi and colleagues, including lead author Vivek Bhaskaran, PhD, a postdoctoral fellow in the Department of Neurosurgery, set out to find groups of microRNAs responsible for regulating complex pathways. Using bioinformatic analysis, the team focused on a group of three microRNAs–miR-124, miR-128 and miR-137–which work as a team in properly developing neurons but are lost during the formation of brain cancer. The team found that several of these microRNAs’ targets included proteins involved in glioblastoma recurrence and resistance to conventional therapies.
The research team tested its findings using multiple cancer cell lines, including glioblastoma as well as non-glioblastoma cell lines. In addition, investigators tested the effectiveness of modulating all three microRNAs at once in a mouse model of intracranial tumors. The team reported a significant survival benefit. Without treatment, the mouse model survived 12 days post-tumor implantation, and chemotherapy extended this to a median of 18 days. But when chemotherapy and the multi-microRNA treatment were combined, survival was extended to a median of 48.5 days.
“These results are very encouraging and may provide a realistic treatment option,” said Bhaskaran.
Peruzzi notes that the multi-microRNA strategy weakens tumor cells but does not directly kill them. “While it seems a bit counterintuitive, this is actually an advantage, since by remaining alive, although severely impaired, cancer cells continue to produce microRNAs which eventually flood the entire tumor.” Indeed, the authors showed that these artificial microRNAs spread through the tumor through tiny vesicles and leave it more vulnerable to chemotherapy.
“We’re coaxing the tumor to produce its own poison, and then we hit it for good with chemotherapy or radiation,” said Peruzzi. “And we’re optimistic that in a relatively short time we can advance this approach to the clinic. A further refined and even more potent version of this concept is already in the pipeline.”
There are currently clinical trials underway at the Brigham leveraging viral vectors and gene therapy approaches for treating glioblastoma (both primary and recurrent). Peruzzi and colleagues are working to further refine their microRNA approach with the goal of using viral vectors to deliver these microRNAs to tumors in brain cancer patients.
Learn more:Â The hitchhiker’s guide to defeating glioblastoma
The Latest on: Glioblastoma
[google_news title=”” keyword=”glioblastoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Glioblastoma
- Glioblastoma Pipeline Landscape Report 2024: Pivotal Advances in Treatment Protocols and Drug Developmentson April 26, 2024 at 1:35 am
The "Glioblastoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest report on the Glioblastoma pipeline insights covers extensive research into the ...
- New Therapy Destroys Deadly Brain Tumor in Dayson April 25, 2024 at 6:30 am
A groundbreaking new therapy destroys deadly brain tumors within days. The new treatment, CAR T-cell therapy, helps treat glioblastoma.
- Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Geneon April 25, 2024 at 5:38 am
Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion ...
- Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meetingon April 24, 2024 at 9:05 am
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical dataUpdated bizaxofusp survival results from the ...
- ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trialon April 23, 2024 at 3:13 am
ITM-31 is a carbonic anhydrase (CA) XII-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177 Lu, ...
- Genetically engineering a treatment for incurable brain tumorson April 22, 2024 at 8:10 am
Purdue University researchers are developing and validating a patent-pending treatment for incurable glioblastoma brain tumors. Glioblastomas are almost always lethal with a median survival time of 14 ...
- 'Shopaholic' author Sophie Kinsella sends message to fans after revealing brain cancer diagnosison April 19, 2024 at 10:32 am
Sophie Kinsella, 54, shared on social media that she has glioblastoma. The author of the "Shopaholic" book series that was turned into a hit movie is sending a message to fans after revealing she is ...
- ‘Confessions of a Shopaholic’ author Sophie Kinsella shares brain cancer diagnosison April 18, 2024 at 8:02 am
Sophie Kinsella says doctors diagnosed her with a glioblastoma in 2022. She's receiving treatment for the aggressive cancer and is 'stable.' ...
- 'Shopaholic' author Sophie Kinsella reveals brain cancer diagnosison April 17, 2024 at 10:08 am
The author of the "Shopaholic" book series that was turned into a movie is battling glioblastoma, a cancerous and aggressive brain tumor. "I did not share this before because I wanted to make sure ...
- Sophie Kinsella, ‘Shopaholic’ Author, Says She Has Brain Canceron April 17, 2024 at 9:21 am
The author of the best-selling book series said she had been undergoing treatment for glioblastoma, an aggressive brain tumor, after a diagnosis in 2022.
via Bing News